Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout

Esperion has forged its first regional deal for Nexletol and Nexlizet since winning US and EU approvals for the cholesterol fighting drugs, bagging $60 million upfront while securing a pharma partner in Japan.